Safety Profile - Jakavi
Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.
Myelosuppression
Patients who develop anaemia may need blood transfusions. Dose adjustment or...- Twitter Linkedin Facebook Pinterest Google plus
Efficacy
Dose recommendation - Jakavi
Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 and for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusReimbursement - Jakavi
Patient Resources - Jakavi
Safety profile
Reimbursement
Dosing
Jakavi®: PV Patient Brochure (Dutch)
Informatie omtrent de oorzaken, symptomen en leven met PV Download Dutch document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button below